

1 Programmable Fluorescent Aptamer-Based RNA Switches for Rapid 2 Identification of Point Mutations

3
4 Zhaoqing Yan^{1,2,3}, Yudan Li^{2,3}, Amit Eshed^{1,3}, Kaiyue Wu^{2,3}, Zachary M. Ticktin⁴, Vel Murugan⁵,
5 Efrem S. Lim⁶, Fan Hong^{7,8*}, Alexander A. Green^{1,2,3*}
6

7 ¹ Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA

8 ²Molecular Biology, Cell Biology & Biochemistry Program, Graduate School of Arts and
9 Sciences, Boston University, Boston, MA 02215, USA

10 ³Biological Design Center, Boston University, Boston, MA 02215, USA

11 ⁴Biodesign Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona
12 State University, Tempe, AZ, USA

13 ⁵Biodesign Virginia G. Piper Center for Personalized Diagnostics at the Biodesign Institute,
14 Arizona State University, Tempe, AZ, USA

15 ⁶Biodesign Center for Fundamental and Applied Microbiomics at the Biodesign Institute, Arizona
16 State University, Tempe, AZ, USA

17 ⁷Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

18 ⁸J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida,
19 Gainesville, FL 32611, USA
20

21 *Correspondence: aagreen@bu.edu, fanhong@ufl.edu
22

23 ABSTRACT

24 The ability to detect single-nucleotide polymorphisms (SNPs) is critical for identifying genetic
25 disorders, assessing pathogen drug resistance, and preventing infection transmission. Achieving
26 a delicate balance across sequence-specific recognition, RNA structural stability, and functional
27 efficacy based on SNP-induced changes in RNA structure is crucial to precise genotyping using
28 RNA-based probes. Here, we report an in silico-designed aptamer-based RNA switch we term
29 FARSIGHT (for **F**ast **A**ptamer-based **R**eporter for **S**ingle-nucleotide-specific **G**enotyping through
30 **H**ybridiza**T**ion) that provides rapid, low-leakage, and multiplexed identification of virtually any
31 target sequence in as little as 5 minutes with single-nucleotide specificity. Coupling FARSIGHTs
32 with nucleic acid sequence-based amplification (NASBA) enables robust detection of single-
33 nucleotide mutations at attomolar concentrations with strong fluorescence output. To evaluate
34 these assays, we deploy them to distinguish the SARS-CoV-2 Omicron variant from other SARS-
35 CoV-2 variants (Alpha, Beta, and Gamma) with 100% accuracy on RNA extracted from clinical

36 saliva samples, as confirmed by reverse transcription quantitative polymerase chain reaction and
37 genomic sequencing. FARSIGHTs can thus be easily reprogrammed for genotyping new
38 pathogens with pandemic potential, with potential uses in point-of-care settings for monitoring of
39 emerging infectious diseases and for personalized healthcare applications.

40

41 **INTRODUCTION**

42 Single-nucleotide polymorphisms (SNPs) and single-nucleotide variants (SNVs) are crucial
43 factors influencing a variety of biological processes ranging from protein function¹ to disease
44 susceptibility², response to medication³, and evolutionary adaptation⁴. Mutations occur frequently
45 in the genome and have far-reaching effects on cell function. Meanwhile, small mutations can
46 drive virus adaptation through genetic changes that abolish the target sites of antiviral drugs and
47 improve viral fitness. Indeed, new variants of severe acute respiratory syndrome coronavirus 2
48 (SARS-CoV-2) have been reported to be 70% more contagious than earlier ones^{5,6} and studying
49 the emergence and propagation of these mutations can be helpful in understanding evolution and
50 disease mechanisms. Despite the profound impact of single-nucleotide changes, detecting these
51 minute changes can be challenging without sophisticated instrumentation.

52 Genomic sequencing and microarray technologies have been widely used for detecting
53 genetic mutations⁷⁻⁹. Yet, these methods are typically limited to central laboratories because of
54 the need for complex equipment, expensive reagents, and trained personnel. Clustered regularly
55 interspaced short palindromic repeats (CRISPR)-based diagnostics hold a promising for detecting
56 genetic variations¹⁰, but they require that mutations are located near a PAM region¹¹⁻¹³ or within
57 a narrow window¹⁴⁻¹⁷ in the targeting region. We previously reported RNA-based single-
58 nucleotide-specific programmable riboregulators (SNIPRs) that leverage small variations in
59 hybridization energy stemming from the distinctions in the target RNA sequence¹⁸. However, the

60 speed of SNIPRs is limited by the time needed to translated reporter proteins in the cell-free
61 systems, causing reactions to take at least 30 minutes¹⁸. Strand-displacement probes have been
62 used in MARVE to provide rapid colorimetric mutation detection based on enzymatic cleavage of
63 urea, but these probes are limited to detecting a single target per reaction¹⁹. Therefore, there
64 remains a need to develop rapid, low-cost, low-leakage, and multiplexed point-of-care diagnostic
65 technologies for identification of single-nucleotide mutations.

66 Fluorescent RNA aptamers are a class of RNA molecules that bind to specific fluorogenic
67 molecules to generate a fluorescent signal²⁰. RNA aptamers are typically discovered through
68 selection processes^{20–22}. Many different types of fluorescent RNA aptamers have been selected
69 with varying emission wavelengths and providing optimized quantum efficiencies^{23–29}. Since the
70 discovery of the fluorescent RNA aptamers³⁰, they have been widely used in bioanalysis and
71 bioimaging as fluorescent probes^{31–34}. The most straightforward way to utilize a fluorescent RNA
72 aptamer is by fusing its sequence to RNA targets as a reporter, enabling the detection of target
73 RNA molecules either through fluorescent imaging or a fluorimeter^{33–36}. Because the fluorescent
74 RNA aptamer must fold into the correct structure to generate a fluorescent signal, an alternative
75 approach involves designing a target-dependent molecular reconfiguration from a non-fluorescent
76 state to a fluorescent state through splitting^{31,32,37,38} or refolding^{39–41} of the RNA aptamer. Recently,
77 we reported aptamer-based switches that employ a toehold-mediated mechanism for rapid
78 detection of different pathogens from clinical samples⁴¹. However, none of these methods can
79 provide finer sequence information within a target RNA, such as identifying point mutations.

80 Herein, we introduce a class of fluorescent RNA switches based on fluorescent aptamers
81 termed FARSIGHTs (for **F**ast **A**ptamer-based **R**epporter for **S**ingle-nucleotide-specific **G**enotyping
82 through **H**ybridiza**T**ion) that can identify single nucleotide mutations in an RNA target with high
83 discrimination performance without the assistance of enzymes. The FARSIGHT design consists
84 of two regions: the target recognition region and the fluorescent RNA aptamer configuration region.

85 In the absence of the mutation of interest in the RNA target, the RNA switch remains in its original
86 state, and no fluorescent signal is generated. However, the target recognition region can identify
87 single-nucleotide mutations in an enzyme-free manner and trigger reconfiguration of the RNA
88 aptamer region through a stabilized basal stem, which refolds to bind to the small fluorogenic
89 ligand molecule, releasing a fluorescent signal in as little as 5 min. This design is universal and
90 can be applied to identify any mutation using different fluorescent RNA aptamers, such as Broccoli,
91 Corn, and Red Broccoli, enabling multiplexed mutation identification. Moreover, the switch can be
92 integrated with isothermal amplification reactions to identify mutations from clinical samples with
93 sensitivity comparable to reverse transcription quantitative PCR (RT-qPCR). For whole RNA
94 extracted from 23 clinical saliva samples, multiplexed assays using FARSIGHTs simultaneously
95 distinguish SARS-CoV-2 Omicron variants from SARS-CoV-2 variants Alpha, Beta, and Gamma
96 with an accuracy of 100% concordant with RT-qPCR and genomic sequencing. Overall, this study
97 not only provides valuable tools for studying RNA structure and function but also opens up new
98 avenues for designing programmable molecular devices with applications ranging from disease
99 biomarker detection to advanced aptamer-based regulatory elements that operate in vivo.

100

101 **RESULTS**

102 **FARSIGHT Design Principles**

103 To implement aptamer-based systems with single-nucleotide specificity, we took advantage of
104 two design principles exploited by previous highly specific detection systems. First, toehold
105 exchange probes⁴² and related systems like SNIPR¹⁸ have achieved SNP detection by using
106 strand-displacement reactions that operate near chemical equilibrium. These toehold exchange
107 systems employ forward and reverse toehold regions of similar binding energies to enforce
108 sequence-specific release of a single-stranded reporter when the correct sequence is detected
109 (**Fig. 1a**). When the target sequence has a single-base difference, the resulting mismatch leads

110 to a significant energy penalty that prevents release of the single-stranded domain. Second,
111 studies with fluorescent RNA aptamers have demonstrated that the binding of fluorogenic
112 molecules to the aptamer only occurs when it is properly folded with an intact basal stem^{20,23,41}.
113 Accordingly, formation of the aptamer basal stem can be used to turn on aptamer fluorescence
114 when a target nucleic acid binds. To reconcile these two strategies, which require release of a
115 single-stranded domain and formation of a stem structure, respectively, we adopted an alternative
116 mechanism for FARSIGHTs that employs a domino-like intramolecular interaction to trigger
117 aptamer folding.

118 As shown in **Fig. 1b**, the FARSIGHT design makes use of a pair of coupled toehold
119 exchange reactions engineered that link RNA binding to aptamer stem formation. The two
120 FARSIGHT toehold exchange reactions take place at two hairpin sites and make use of 3- to 6-
121 nt forward and reverse toehold sites that can spontaneously hybridize or disassociate in typical
122 reaction conditions. The two FARSIGHT hairpins also prevent folding of the reporter aptamer,
123 resulting in minimal fluorescence in the absence of the target RNA. When the target first interacts
124 with the FARSIGHT probe, it binds strongly to an extended ~20-nt FARSIGHT docking region,
125 previously used in SNIPRs¹⁸, providing it a stable site from which to initiate subsequent
126 interactions as a quasi-unimolecular complex. In the first toehold exchange reaction, the target
127 RNA binds to the forward toehold domain **a**, and the ensuing branch migration reaction disrupts
128 the first FARSIGHT stem through to the reverse toehold domain **e**. This toehold domain opens
129 spontaneously and thus completes the exchange reaction when a target with the correct
130 sequence binds. Completion of this first strand-displacement reaction establishes the intermediate
131 state of the FARSIGHT-target complex, and the transition energy ($\Delta G_{\text{OFF-INT}}$) of the reaction is
132 controlled by the forward toehold domain **a** and reverse toehold domain **d**. The newly released
133 single-stranded domains **c*** and **b*** from this reaction are then free to initiate the second toehold
134 exchange reaction with the forward toehold domain **b** in the second FARSIGHT stem region. The

135 ensuing branch migration reaction proceeds until it reaches the second reverse toehold domain
136 **e**, which unwinds spontaneously to complete the reaction. The second strand-displacement
137 reaction yields the ON state of the FARSIGHT-target complex with the transition energy ($\Delta G_{\text{INT-ON}}$)
138 of the reaction controlled by the forward toehold domain **b** and reverse toehold domain **e**.
139 Importantly, the second toehold exchange process leads to formation of the aptamer basal stem,
140 which promotes proper aptamer folding. Once the reporter aptamer folds, it binds to the cognate
141 fluorogen to generate a fluorescent readout signal.

142 From this base design, FARSIGHTs must satisfy three key rules to reliably identify point
143 mutations: (1) the toehold and branch migration domains of the first toehold exchange reaction
144 must perfectly match with the cognate region of the mutant target, (2) the equilibrium energy
145 between the OFF state and intermediate state $\Delta G_{\text{OFF-INT}}$ should be designed to be around -1
146 kcal/mol, and (3) the equilibrium energy between the intermediate state and the ON state $\Delta G_{\text{INT-ON}}$
147 should also be designed to be -1 kcal/mol or lower. Therefore, the first strand displacement
148 reaction is a slightly thermodynamically favorable step, and the intermediate state will be the
149 dominant state upon the binding of mutant target with the correct sequence. However, in the
150 presence of the WT target, which does not have the correct sequence, the resulting mismatch will
151 leave a single-nucleotide bulge in the intermediate state (**Fig. 1b, Supplementary Table 1**). The
152 bulge will cause a ~ 4 kcal/mol energy penalty and shift the equilibrium energy of the transition
153 between the OFF state to intermediate state to ~ 3 kcal/mol. Consequently, the first toehold
154 exchange reaction becomes unfavorable upon the binding of WT targets. In the event that the
155 first reaction proceeds, the second toehold exchange reaction provides a final check on sensor
156 activation through two mechanisms. First, it impedes fluorogen-driven aptamer folding, which
157 would otherwise contribute to signal leakage. Second, it delays aptamer folding and thus provides
158 additional time to reverse the first strand displacement for incorrect targets. Overall, the use of
159 the coupled toehold exchange reactions enables us to tune the favorability of the sensor activation

160 steps depending on the point mutation of interest in the RNA target and the aptamer/fluorogen
161 pair.

162 We developed a biochemical model to capture the key steps of the FARSIGHT performance,
163 including the first and the second step strand displacement with the binding of fluorogenic
164 molecules (see **Supplementary Note 1** and **Supplementary Fig. 1-2** for details). A combination
165 of different chemical equilibrium energies for the two-step strand-displacement reaction has been
166 systematically explored. As shown in **Fig. 1c**, the optimal FARSIGHT design will have an
167 equilibrium energy ranging from -2 to 2 kcal/mol for the transition from OFF state to Intermediate
168 state and an equilibrium energy ranging from -1.5 to -15 kcal/mol for the second transition from
169 Intermediate state to ON state. The energy of this second transition does not include the binding
170 energy of the fluorogen to the RNA aptamer.

171

172 **Detection of mutations using FARSIGHTs**

173 We designed an initial FARSIGHT with the Broccoli aptamer and targeted it to the P681R mutation
174 in the SARS-CoV-2 S gene based on the principles described above. The reaction energies for
175 the two toehold exchange reactions are -1.9 kcal/mol and -1.8 kcal/mol, respectively. Well-folded
176 Broccoli aptamer binds to its cognate fluorogen DFHBI-1T with an equilibrium energy of -8.87
177 kcal/mol (see **Supplementary Note 2** for binding analysis), which provides a strong green
178 emission signal under blue-light illumination²³. We then experimentally validated the mutation
179 identification capability of the FARSIGHT design. We in vitro transcribed the FARSIGHT RNAs
180 and incubated them with DFHBI-1T. We found that no fluorescent signal was generated. The
181 addition of mutant RNA target into the incubated mixture gave very strong fluorescent signal within
182 30 minutes, while the addition of WT target yielded minimal fluorescence compared to the control.
183 A typical kinetic curve and fluorescence images upon the blue light illumination are shown in **Fig.**
184 **1d-e (Supplementary Table 1, Supplementary Video).**

185 To systematically study how the equilibrium energy influences FARSIGHT discrimination
186 capability, we designed a set of 99 (see **Supplementary Table 1**) different FARSIGHT RNAs by
187 varying the binding strength of the four different toehold domains. The results are shown in the
188 heatmap in **Fig. 2a** and demonstrate good agreement with the biochemical modeling results in
189 **Fig. 1c**. The small discrepancy between the simulation results and experimental results (~1
190 kcal/mol between the $\Delta G_{\text{OFF-INT}}$) may be attributed to two major factors: (1) inaccuracies in
191 predictions of RNA folding by current RNA free energy prediction models⁴³ and (2) difficulties in
192 accurately representing the intermediate state, which is highly dynamic and has multiple possible
193 structures depending on the FARSIGHT sequence. For example, we observed two designs that
194 yielded identical equilibrium energies for both toehold exchange reactions but provided
195 dramatically different differentiation factors in experiments (**Supplementary Fig. 3** and
196 **Supplementary Table 1**). Despite these limitations, the model can assist in the design of
197 functional FARSIGHTs to target different mutations in an RNA transcript.

198 We further evaluated the capacity of FARSIGHTs to discriminate mutations by examining
199 mutations located at positions 1 to 21 in the target RNA (**Fig. 2b, Supplementary Table 2**), which
200 hybridize from the beginning of the forward toehold to the end of the first branch migration domain.
201 The RNA binding of this region affects the equilibrium between different states. To assess sensor
202 performance, we employed the discrimination factor (D_f), which is defined as the ratio of
203 FARSIGHT fluorescence with the correct target divided by FARSIGHT fluorescence for the
204 incorrect target. This set of targets revealed that the FARSIGHT probe could discriminate
205 mutations at all 21 target positions. We also found that mutations that convert canonical Watson-
206 Crick base pairing to G-U wobble base pairing can also be distinguished, such as the A->G
207 mutation at position 20 and C->U at position 15. However, mutations at positions 16 to 19 yielded
208 the best discrimination results, providing discrimination factors all above 50. Although mutations
209 at either the toehold or branch migration domain will have the same influence on the chemical

210 equilibrium energy, the improved specificity at positions 16 to 19 suggests additional contributions
211 from kinetic effects. In particular, mutations at positions 16 to 19, which displace the FARSIGHT
212 b* domain, likely provide a stronger kinetic trap to prevent FARSIGHT activation for mutations in
213 this region by inhibiting release of the toehold-binding domain for the second strand-displacement
214 step.

215

216 **Automated in silico Design of FARSIGHTs and Rapid Validation in vitro.**

217 To test the universality of FARSIGHTs for clinically relevant mutations, we generated a set of
218 FARSIGHTs to target critical mutations in the SARS-CoV-2 RNA genome (**Fig. 3a**,
219 **Supplementary Table 3**) using computational design (see **Supplementary Note 2**). We selected
220 mutations that defined different SARS-CoV-2 variant strains that evolved during the COVID-19
221 pandemic, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and
222 Omicron (B.1.1.529) as well as its sublineages (see **Supplementary Fig. 4a**). The resulting
223 FARSIGHT transcripts were then systematically evaluated for specificity by challenging them with
224 synthetic versions of the SARS-CoV-2 wild-type or mutant sequences after in vitro transcription.
225 The discrimination factor was determined for each of these FARSIGHTs to quantitate their
226 discriminatory capacity.

227 **Figure 3b** shows the discrimination performance of the systems using Broccoli as the
228 output aptamer. From these rapid screening experiments (**Supplementary Fig. 4b** and
229 **Supplementary Table 4**), we find that all target mutants can be distinguished from the wild-type
230 sequences to facilitate the recognition of viral variants (**Supplementary Fig. 5a** and
231 **Supplementary Table 4**). Out of this set, the top-performing FARSIGHT provided a large ≥ 90 -
232 fold increase in fluorescence upon discrimination of the cognate mutant compared to reactions
233 with wild-type sequence, and half of the FARSIGHTs yielded discrimination factors of at least 10.

234 Clearly visible is the strong green fluorescence produced by the Broccoli FARSIGHTs containing
235 the SARS-CoV-2 target RNA carrying the targeted mutations (**Fig. 3c**). **Figure 3d-g** and
236 **Supplementary Fig. 5b-I** show time-course measurements of the sensors profiling activation
237 speed and leakage of the sensors in 37°C reactions. Statistically significant fluorescence signals
238 can be detected after 5 minutes of reaction in a plate reader for the fastest sensors and strong
239 activation is observed within 30 minutes for the optimal Broccoli FARSIGHT designs. Impressively,
240 for the reactions with wild-type RNA without the targeted mutations, only near-background
241 fluorescence could be observed in many of the sensors.

242

243 **Multiplexed detection of point mutations using FARSIGHTs with different aptamer outputs**

244 The rapid and accurate identification of multiple mutations in a single test can be especially useful
245 in monitoring the evolution and dynamics of viral populations and help healthcare professionals
246 make appropriate treatment decisions. The design of FARSIGHTs, as described here, can be
247 adapted for use with a wide range of fluorogenic aptamers, including but not limited to Broccoli,
248 Corn, and Red Broccoli, which could be used to increase assay multiplexing capacity or allow it
249 to be interpreted by other fluorescence detection systems (**Fig. 4a**). Red Broccoli and Corn
250 FARSIGHTs were designed for targeting a series of mutations characteristic of SARS-CoV-2
251 variants (**Supplementary Fig. 6-7, Supplementary Table 5-6**). **Figure 4b-c** shows the
252 performance evaluation for a library of 7 Red Broccoli FARSIGHTs targeting the sense orientation
253 or antisense orientation of the mutant target sequence. Red Broccoli FARSIGHTs exhibited
254 differentiation factors of over 10 for most of the mutant targets with a very low level of leakage
255 and fast activation time with strong fluorescence occurring within 15 minutes (**Fig. 4c,**
256 **Supplementary Fig. 6b-g**). The FARSIGHT designs with Corn were also successful in detecting
257 different target mutations as shown in **Fig. 4d-e** and **Supplementary Fig. 7**. These Corn

258 FARSIGHTs display lower ON/OFF ratios compared to the Broccoli-based systems as they emit
259 relatively weaker fluorescence output with a weaker reliance on a strong basal stem⁴¹.

260 We then moved on to differentiate multiple mutations with three aptamers having spectrally
261 distinct fluorescence. The V1176F (for characterizing Gamma) and P681H (for characterizing
262 Alpha) S gene mutations were detected using orthogonal FARSIGHTs with Broccoli/DFHBI-1T
263 and Corn/DFHO outputs, respectively, in the same reaction (**Supplementary Fig. 8a**,
264 **Supplementary Table 7**). Similarly, as shown in **Supplementary Fig. 8b**, the orthogonal
265 FARSIGHTs with Broccoli/DFHBI-1T and Red Broccoli/OBI outputs also recognized all
266 combinations of N969K (for all Omicron variants) and G496S (for Omicron BA.1 sub-variant) S
267 gene mutations. For triplex detection, all combinations of V1176F, P681H, and Q493R S gene
268 mutations were successfully detected by FARSIGHTs programmed with Broccoli/DFHBI-1T,
269 Corn/DFHO, and Red Broccoli/OBI, respectively (**Fig. 4f**, **Supplementary Table 7**).

270

271 **Integration with isothermal amplification for low concentration RNA targets**

272 Accurate identification of viral variants of interest from other variants is crucial for the early
273 detection and management of emerging outbreaks. We coupled FARSIGHTs with nucleic acid
274 sequence-based amplification (NASBA) reactions⁴⁴, which enable nucleic acid amplification at a
275 constant 37°C to 42°C temperature for detecting clinically relevant RNA concentrations⁴⁵ (**Fig. 5a**).
276 NASBA begins with a reverse primer that facilitates reverse transcription of the target RNA,
277 forming an RNA/DNA duplex. RNase H degrades the RNA template, allowing a forward primer
278 with a T7 promoter to bind and initiate elongation of the complementary strand, creating a double-
279 stranded DNA product. T7-mediated transcription of the DNA template generates multiple copies
280 of the target RNA sequence^{44,46}.

281 NASBA primer sets for the SARS-CoV-2 RNA genome were designed and screened
282 experimentally (**Supplementary Fig. 9**, **Supplementary Table 8**). The optimal primer pairs were

283 then combined with the top-performing FARSIGHTs from screening tests for a series of
284 experiments supplying 80-minute amplification reactions with different concentrations of cultured
285 variant SARS-CoV-2 RNA containing either the target mutation or WT SARS-CoV-2 RNA (**Fig. 5,**
286 **Supplementary Fig. 10, Supplementary Table 9**). We designed the FARSIGHT to target the
287 F490S S gene mutation^{47,48} to identify the XBB Omicron subvariant of SARS-COV-2. As shown
288 in **Fig. 5b-c**, upon coupling with NASBA, the Red Broccoli and Broccoli FARSIGHTs targeting
289 F490S displayed a substantial fluorescence increase for XBB RNA template concentrations down
290 to 30 RNA copies/ μ L, yet the reactions utilizing cultured wild-type or Omicron BA.1 SARS-CoV-2
291 variants only provided low fluorescence. The detection limits achieved using our approach are
292 sufficient for detection of the virus from clinical samples^{49,50}.

293

294 **SNP-identification of SARS-CoV-2 variants in clinical saliva samples**

295 We then applied the NASBA-integrated FARSIGHT assay to detect the SARS-CoV-2 virus and
296 further identify the specific variant in clinical saliva samples. We used two designed FARSIGHTs
297 to detect the N501Y and Y505H mutations with Broccoli and Red Broccoli (**Fig. 6a,**
298 **Supplementary Table 9**), respectively. The mutation N501Y exists in all the major SARS-CoV-2
299 variants⁵¹, and Y505H is a hallmark mutation for the Omicron variant^{52,53}. Synthetic virus RNA
300 fragments from Omicron and Alpha variants were first used to validate the two FARSIGHTs. We
301 used the 95th percentile values of 33 Alpha RNA samples and 35 SARS-CoV-2 negative samples
302 to determine the threshold value (arbitrary units (AU)) for identifying Omicron variants (882.5 AU
303 from Red Broccoli FARSIGHTs) and general SARS-CoV-2 variants (2329.7 AU from Broccoli
304 FARSIGHTs), respectively (**Supplementary Fig. 12a**). As shown in **Fig. 6b**, the Omicron RNA
305 genome fragments can turn on the fluorescence signal in both green and red channels for the two
306 FARSIGHTs, resulting in orange output fluorescence. The Alpha variant can only activate the
307 fluorescent signal in the green channel from the FARSIGHT targeting N501Y. Similarly, this

308 strategy can also be adopted to identify XBB subvariant (F490S mutation) from general Omicron
309 variants (Y505H mutation) or identify the Omicron BA.1 variant (G496S) from major SARS-CoV-
310 2 (N501Y mutation) variants (**Supplementary Fig. 11, Supplementary Table 10**).

311 We next validated the FARSIGHT dual-site discrimination assay using clinical saliva
312 samples from 12 positive and 11 negative patients and compared with RT-qPCR test. The viral
313 RNA sample was extracted from the saliva and applied to the NASBA-coupled FARSIGHT assay.
314 All the positive patient samples gave a strong fluorescent signal increase in both green and red
315 channels (**Fig. 6c, Supplementary Fig. 13**), and negative samples did not show significant signal
316 change in either channel (**Fig. 6d, Supplementary Fig. 14**). These results indicate that all the
317 positive patients are infected by the Omicron variants, aligning well with the dominance of the
318 Omicron variant in the US when the samples were collected. The RT-qPCR and FARSIGHT
319 results for the samples matched very well displaying complete concordance (**Supplementary Fig.**
320 **12b**).

321

322 **DISCUSSION**

323 We have developed FARSIGHTs, RNA switches that couple fluorescent aptamer-based readout
324 with robust single-nucleotide mutation discrimination capabilities. FARSIGHTs exploit a coupled
325 pair of toehold exchange reactions that operate at exquisitely designed chemical equilibrium and
326 achieve high sequence specificity. We have demonstrated that FARSIGHTs are compatible with
327 multiple fluorescently distinct aptamers, enabling one-pot multiplexed mutation detection, and can
328 successfully identify arbitrary mutations, including those generating G-U wobbles. Through
329 integration with isothermal amplification reactions, FARSIGHTs can detect mutations in low-
330 abundance RNA targets extracted from clinical saliva samples. When paired with a portable
331 fluorescent reader and lyophilization of the necessary biological reagents, FARSIGHTs hold

332 significant promise as a convenient diagnostic system for detecting mutations in diverse settings,
333 including homes, hospitals, and field environments.

334 Compared with RNA sequencing^{54,55} and PCR-based⁵⁶ methods commonly employed in
335 central laboratories, FARSIGHTs require a significantly lower cost of ~\$1.76 per reaction (see
336 **Supplementary Note 3**), a simpler equipment setup, and provide a faster turnaround time without
337 requiring companion enzymes for readout. Moreover, they have several advantages over recently
338 developed mutation detection methods. For instance, use of CRISPR-Cas enzymes for mutation
339 detection necessitates a protospacer adjacent motif (PAM) sequence in the double-stranded DNA
340 target or provides point mutation detection in only a small sequence region in single-stranded
341 targets based on the seed region of the spacer^{57,58}, while FARSIGHTs can resolve point mutations
342 that occur over a 21-nt window. In comparison to FARSIGHTs, SNIPRs can generate colorimetric
343 outputs, but they have slower reaction times and require more sophisticated and costly cell-free
344 expression systems to generate signal because of their translation-based output^{18,59}. Similarly,
345 the utilization of conventional toehold exchange probes demands costly modifications involving
346 dyes and quenchers for each target, thus increasing development and deployment costs.
347 Although the use of unmodified toehold exchange DNA probes in MARVE decreases its cost¹⁹,
348 the colorimetric readout of MARVE relies on urease activity and is incompatible with one-pot
349 multiplexing.

350 The design of FARSIGHTs provides new insight into the integration of RNA folding control
351 with its biological roles. RNA's function is related to its diverse structures, and the design of
352 functional RNA molecular devices thus demands control of RNA folding for a variety of different
353 structure types. Conventional single-step strand-displacement reactions are aptly suited for
354 release of single-stranded RNA functional motifs. Indeed, this approach has been used to control
355 gene translation^{18,60–62}, transcription⁶³, and genome editing^{64,65}. However, there are many cases
356 where a functional RNA must fold into fully or partially double-stranded states to operate, such as

357 aptamers^{23–25,27,41,66}, ribozymes^{67–69}, tRNAs^{70,71}, and microRNA precursors^{72,73}. Using the domino-
358 like toehold exchange reactions of FARSIGHTs, we expect that it will be possible to not only
359 regulate the function of stem-containing functional RNAs but to make them responsive to minute
360 sequence differences in target transcripts.

361 Since the FARSIGHT mechanism relies on small differences in folding free energy, it is
362 possible that a variety of other target molecules could be detected using similar strategies based
363 on intramolecular refolding. For instance, RNA modifications are known to affect the binding
364 affinity of RNAs^{18,74} and could thus be differentiated by FARSIGHTs. Furthermore, FARSIGHT-
365 based detection could be extended to other types of molecules, such as small molecules^{75,76} or
366 proteins^{77–79}, when their RNA binding motif is embedded into the first step of strand displacement
367 to shift chemical equilibrium to favor aptamer folding. FARSIGHTs also have great potential to
368 visualize mutations in live cells. Fluorescent RNA aptamers have been widely used for live-cell
369 RNA imaging^{32,80,81}, but these aptamer-based probes have not demonstrated single-nucleotide
370 specificity for spatial profiling at the single-cell level. FARSIGHTs that operate in live cells could
371 allow us to study the occurrence of genome mutation in real time, providing deeper spatial and
372 temporal information into biological processes such as DNA damage and repair^{82,83}. We thus
373 envision that FARSIGHTs and systems with similar mechanisms will provide valuable new
374 insights into cell biology and wide biomedical applications in the future.

375

376 **MATERIALS AND METHODS**

377 **FARSIGHT preparation**

378 All DNA oligonucleotides were designed using the NUPACK software package as briefly
379 described in the Results section and purchased from IDT (Integrated DNA technologies, Inc.).
380 DNA fragments were assembled from 1 or 2 T7 promotor-having ssDNA templates with a $T_m =$
381 57 °C overlap region via PCR using Phusion High-Fidelity PCR Master Mix with HF Buffer (NEB,

382 M0531L). FARSIGHT RNAs were transcribed from assembled PCR products (200 nM) in vitro
383 using AmpliScribe™ T7-Flash™ Transcription Kits (Lucigen, ASF3507) from the DNA template
384 at 37 °C for 4 hours. All transcription products were used without further purification unless
385 otherwise noted.

386

387 **RNA target preparation**

388 Synthetic target RNA for FARSIGHT *in vitro* validation experiments was directly transcribed from
389 PCR-amplified product and was purified using Monarch® RNA Cleanup Kit (NEB, T2040L). RNA
390 concentration was then determined by measuring the absorbance at a wavelength of 260 nm.
391 The concentration for the synthetic target applied to the reactions was about 2 μM.

392 Full-genome synthetic SARS-CoV-2 variant RNA (controls 15, 16, 17, 23, 48 and 50) for
393 other experiments (e.g. LoD tests, two-site simultaneous detection, and clinical samples
394 validations) were purchased from Twist Bioscience. Full-genome reference SARS-CoV-2 RNA
395 from heat-inactivated culture virions (VR-1986HK™, Wild-type sequences) were purchased from
396 ATCC.

397

398 **Readout of FARSIGHT reactions**

399 A BioTek Synergy Neo2 multimode microplate reader (Agilent, NEO2MALPHAT) was used for all
400 plate reader measurements. 1 μL direct FARSIGHT transcription product and 2.5 μM of purified
401 target RNA was added to a 384-well plate along with 4 μM of DFHBI-1T for Broccoli (Lucerna,
402 410), 2 μM of DFHO for Corn (Lucerna, 500), or 4 μM of OBI for Red Broccoli (Lucerna, 610).
403 DFHBI-1T, DFHO, and OBI buffers consist of 40 mM HEPES (Gibco™, 15630080), pH 7.4, 100
404 mM KCl (Invitrogen™, AM9640G), and 5 mM MgCl₂ (Invitrogen™, AM9530G). Before each
405 measurement, samples were shaken linearly for 30 seconds to ensure proper mixing. The plate

406 reader was pre-heated, and the measurements were taken at 37°C unless otherwise noted.
407 Fluorescence intensity values were corrected by subtracting the background fluorescence
408 obtained from a blank control sample containing the FARSIGHT reaction without any RNA or DNA.

409

410 **Imaging of FARSIGHT reactions**

411 To observe the fluorescence of the sensors, we illuminated the reactions in a microplate using a
412 Safe Imager 2.0 Blue Light Transilluminator (Thermo Fisher, G6600). Videos and images of
413 fluorescent reaction were taken by a standard cellphone camera (iPhone 14 Pro or iPhone 12,
414 Apple Corp.).

415

416 **In-sample multiplexed point mutation tests**

417 The two-input reactions with Corn and Broccoli outputs were prepared with 2 μ L Corn
418 FARSIGHT/1.7 μ M DFHO fluorogen and 1 μ L Broccoli FARSIGHT/4 μ M DFHBI-1T fluorogen.
419 The 10X fluorogenic dye mix consisted of 17 μ M DFHO (Lucerna, 500), 40 μ M DFHBI-1T
420 (Lucerna, 410), 40 mM HEPES (Gibco™, 15630080), pH 7.4, 100 mM KCl (Invitrogen™,
421 AM9640G), and 5 mM MgCl₂ (Invitrogen™, AM9530G).

422 The two-input reactions with Red Broccoli and Broccoli outputs were prepared with 1 μ L
423 Red Broccoli FARSIGHT/4 μ M OBI fluorogen and 1 μ L Broccoli FARSIGHT/4 μ M DFHBI-1T
424 fluorogen. The 10X fluorogenic dye mix consisted of 40 μ M OBI (Lucerna, 610), 40 μ M DFHBI-
425 1T (Lucerna, 410), 40 mM HEPES (Gibco™, 15630080), pH 7.4, 100 mM KCl (Invitrogen™,
426 AM9640G), and 5 mM MgCl₂ (Invitrogen™, AM9530G).

427 The three-channel reactions were prepared with 2 μ L Corn FARSIGHT/2 μ M DFHO
428 fluorogen, 1 μ L Red Broccoli FARSIGHT/4 μ M OBI fluorogen and 1 μ L Broccoli FARSIGHT/4 μ M

429 DFHBI-1T fluorogen. The 10X fluorogenic dye mix consisted of 20 μ M DFHO (Lucerna, 500), 40
430 μ M DFHBI-1T (Lucerna, 410), 20 μ M OBI (Lucerna, 610), 40 mM HEPES (Gibco™, 15630080),
431 pH 7.4, 100 mM KCl (Invitrogen™, AM9640G), and 5 mM MgCl₂ (Invitrogen™, AM9530G).

432

433 **NASBA/FARSIGHT reactions**

434 10 μ L NASBA reactions⁴⁴ were carried out using the following protocol: 3.35 μ L reaction buffer
435 (Life Sciences, NECB-24; 3X), 1.65 μ L nucleotide mix (Life Sciences NECN-24; 6X), 0.2 μ L of
436 each DNA primer (IDT, 12.5 μ M) and 2.3 μ L RNA input were assembled at room temperature.
437 After being incubated at 65 °C for 2 min and a 5 min incubation at 41 °C, 2.5 μ L of enzyme mix
438 (Life Sciences, NEC-1-24) was added to the reaction. The reaction took place at 41 °C for 80 min,
439 then 10 μ L of amplification product was applied to the FARSIGHT reactions with the FARSIGHT
440 sensor and cognate fluorogen (1 μ L Corn/2 μ M DFHO, 1 μ L Red Broccoli FARSIGHT/4 μ M OBI,
441 or 1 μ L Broccoli/4 μ M DFHBI-1T).

442

443 **Simultaneous detection of mutations at two sites from a NASBA product**

444 The 10X fluorogenic dye mix in this reaction is consisted of 40 μ M DFHBI-1T (Lucerna, 410), 40
445 μ M OBI (Lucerna, 610), 40 mM HEPES (Gibco™, 15630080), pH 7.4, 100 mM KCl (Invitrogen™,
446 AM9640G), and 5 mM MgCl₂ (Invitrogen™, AM9530G).

447 The reaction for simultaneously detecting two point mutations from NASBA product was
448 prepared for according to the following recipe: 3.5 μ L 10X fluorogenic dye mix, 1.0 μ L transcribed
449 Broccoli FARSIGHT, 1.0 μ L transcribed Red Broccoli FARSIGHT, 10 μ L NASBA product, 19.5 μ L
450 DNase/RNase-Free Distilled Water (Invitrogen™, 10977023). The reaction was then incubated in
451 a plate in a temperature-controlled plate reader (Agilent, NEO2MALPHAT) with the
452 Broccoli/DFHBI-1T (Excitation: 472/20, Emission: 507/20) and Red Broccoli/OBI (Excitation:

453 541/20, Emission: 590/20) fluorescence read out taken in real time at a 37°C constant
454 temperature.

455

456 **Clinical virus sample collection and processing**

457 Clinical saliva samples were obtained from the Biodesign Institute Clinical Testing Laboratory
458 (Arizona State University). The specimens were collected for SARS-CoV-2 diagnostic purposes
459 with the consent of the patients and provided as de-identified clinical remnants under the oversight
460 of the Arizona State University Institutional Review Board (IRB ID: STUDY00011737). The viral
461 RNA was extracted using PureLink™ Viral RNA/DNA Mini Kit (Thermo Fisher, 12280050)
462 according to the manufacturer's instructions. RNA was eluted with 50 μ l H₂O and stored at -80°C
463 before use.

464

465 **Reference RT-qPCR reactions**

466 Parallel RT-qPCR detection was implemented using the Luna® SARS-CoV-2 RT-qPCR Multiplex
467 Assay Kit Detection (NEB, E3019). The detection procedure was conducted according to the
468 protocol provided by the kit in 7900HT Fast Real-Time PCR System with 384-Well Block Module
469 (Thermo Fisher, 4329001). Time to threshold was calculated using single threshold analysis mode.

470

471 **SARS-CoV-2 sequencing**

472 Whole genome sequencing was performed on saliva specimens RNA extracts as previously
473 described⁸⁴. In brief, library preparation was performed using COVIDSeq Test (Illumina,
474 20043675) and sequenced on the Illumina NextSeq 2000 instrument using 2 x 109 paired end
475 reads. Sequencing reads were trimmed and quality-filtered to assemble high quality genomes.
476 Sequence quality was validated using VADR (version 1.4)⁸⁵, and lineage calling was performed
477 using Pangolin⁸⁶. All genome sequences were deposited to the GISAID repository.

478

479 **Statistical methods**

480 Plate reader dataset analysis and illustrations were performed using MATLAB, SnapGene Viewer,
481 GraphPad Prism, Microsoft Excel, and Adobe Illustrator. Averages of plate reader measurements
482 taken for FARSIGHT reactions were conducted using the arithmetic mean of each technical
483 replicate. Error bars show the standard deviation from three biological technical replicates ($n = 3$)
484 for the fluorescent measurements. Two-tailed Student's t test calculations were conducted to
485 determine statistical significance in GraphPad Prism. The 95th percentile calculation to assess the
486 diagnostic sensitivity, specificity and accuracy of the FARSIGHT assay were produced using
487 Microsoft Excel.

488

489 **Acknowledgments**

490 We thank the Biodesign Institute clinical testing laboratory (Arizona State University) for providing
491 COVID-19-relevant patient samples, and Alexis Thomas, Winston Matthews, Remington Fitch,
492 LaRinda Holland and Matthew Smith for assistance with sequencing. This work was developed
493 with funding from the Defense Advanced Research Projects Agency (DARPA), Contract No.
494 N66001-23-2-4042; a National Institutes of Health (NIH) Director's New Innovator Award
495 (1DP2GM126892), U01 award (1U01AI148319-01), and R01 award (1R01EB031893); a National
496 Science Foundation (NSF) RAPID award (2029532); Arizona Biomedical Research Centre funds
497 (ADHS16-162400, CTR051763); Canadian Food Inspection Agency funds (39903-200137) and
498 Boston University startup funds to A.A.G. The views, opinions and/or findings expressed are those
499 of the authors and should not be interpreted as representing the official views or policies of the
500 Department of Defense or the U.S. Government. The content is solely the responsibility of the
501 authors and does not necessarily represent the official views of the National Institutes of Health.

502

503

504 **Data availability**

505 The main data supporting the results in this study are available within the main text and the
506 Supplementary Information. The datasets generated during and/or analyzed during the current
507 study are available from the corresponding authors on reasonable request.

508

509 **Author contributions**

510 Z.Y. and A.A.G. conceived and designed the studies and experiments. Z.Y. performed most of
511 the wet experiments. Y.L. contributed to RT-qPCR on SARS-CoV-2 clinical samples, A.E.
512 contributed to the screening of optimal NASBA primers, and K.W. contributed to selecting
513 hallmark mutations of Omicron variants. Z.M.T. and V.M. acquired the SARS-CoV-2 clinical
514 samples and E.S.L. performed genomic sequencing of the clinical samples. F.H. designed the
515 biochemical modeling simulation. A.A.G. and F.H. supervised the research. Z.Y. performed the
516 analysis of data. Z.Y., F.H. and A.A.G. wrote and edited the manuscript.

517

518 **Declaration of interests**

519 Z.Y. and A.A.G. have a pending provisional patent application related to this work. A.A.G. is a
520 cofounder of En Carta Diagnostics Inc. The authors declare no other competing interests.

521

522 **REFERENCES**


- 523 1. Liao, P. Y. & Lee, K. H. From SNPs to functional polymorphism: The insight into
524 biotechnology applications. *Biochemical Engineering Journal* **49**, 149–158 (2010).
525 2. Hou, Y. *et al.* New insights into genetic susceptibility of COVID-19: An ACE2 and
526 TMPRSS2 polymorphism analysis. *BMC Med* **18**, (2020).
527 3. Shastry, B. S. SNPs in disease gene mapping, medicinal drug development and
528 evolution. *Journal of Human Genetics* **52**, 871–880 (2007).
529 4. Schröder, N. W. J. & Schumann, R. R. Single nucleotide polymorphisms of Toll-like
530 receptors and susceptibility to infectious disease. *Lancet Infectious Diseases* **5**, 156–164
531 (2005).

- 532 5. Khan, A. *et al.* Higher infectivity of the SARS-CoV-2 new variants is associated with
533 K417N/T, E484K, and N501Y mutants: An insight from structural data. *J Cell Physiol*
534 **236**, 7045–7057 (2021).
- 535 6. Hossain, M. K., Hassanzadeganroudsari, M. & Apostolopoulos, V. The emergence of
536 new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? *Expert Rev*
537 *Vaccines* **20**, 635–638 (2021).
- 538 7. Nielsen, R., Paul, J. S., Albrechtsen, A. & Song, Y. S. Genotype and SNP calling from
539 next-generation sequencing data. *Nature Reviews Genetics* **12**, 443–451 (2011).
- 540 8. Syvanen, A. C. Toward genome-wide snp genotyping. *Nat Genet* **37**, S5–S10 (2005).
- 541 9. Kim, S. & Misra, A. SNP genotyping: Technologies and biomedical applications. *Annual*
542 *Review of Biomedical Engineering* **9**, 289–320 (2007).
- 543 10. Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F. & Collins, J. J.
544 CRISPR-based diagnostics. *Nature Biomedical Engineering* **5**, 643–656 (2021).
- 545 11. Chen, J. S. *et al.* CRISPR-Cas12a Target Binding Unleashes Indiscriminate Single-
546 Stranded DNase Activity. *Science* **360**, 436–439 (2018).
- 547 12. Fozouni, P. *et al.* Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and
548 mobile phone microscopy. *Cell* **184**, 323-333.e9 (2021).
- 549 13. De Puig, H., Lee, R.A., Najjar, D., Tan, X., Soenksen, L.R., Angenent-Mari, N.M.,
550 Donghia, N.M., Weckman, N.E., Ory, A., Ng, C.F. and Nguyen, P.Q. Minimally
551 instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of
552 SARS-CoV-2 and emerging variants. *Science advances* **7**, 32 (2021): p.eabh2944.
- 553 14. Gootenberg, J. S. *et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* **356**,
554 438–442 (2017).
- 555 15. Harrington, L. B. *et al.* Programmed DNA Destruction by Miniature CRISPR-Cas14
556 Enzymes. *Science*, **362**, 839-842 (2018).
- 557 16. Myhrvold, C. *et al.* Field-Deployable Viral Diagnostics Using CRISPR-Cas13. *Science*
558 **360**, 444–448 (2018).
- 559 17. Gootenberg, J. S. *et al.* Multiplexed and Portable Nucleic Acid Detection Platform with
560 Cas13, Cas12a, and Csm6. *Science* **360**, 439–444 (2018)
- 561 18. Hong, F. *et al.* Precise and Programmable Detection of Mutations Using Ultraspecific
562 Riboregulators. *Cell* **180**, 1018-1032.e16 (2020).
- 563 19. Zhang, T. *et al.* A paper-based assay for the colorimetric detection of SARS-CoV-2
564 variants at single-nucleotide resolution. *Nat Biomed Eng* **6**, 957–967 (2022).
- 565 20. Bouhedda, F., Autour, A. & Ryckelynck, M. Light-up RNA aptamers and their cognate
566 fluorogens: From their development to their applications. *International Journal of*
567 *Molecular Sciences* **19**, 44 (2018).
- 568 21. Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. *Nature Reviews Drug*
569 *Discovery* **9**, 537–550 (2010).
- 570 22. Wang, T. & Ray, J. Aptamer-based molecular imaging. *Protein and Cell* **3**, 739–754
571 (2012).
- 572 23. Filonov, G. S., Moon, J. D., Svensen, N. & Jaffrey, S. R. Broccoli: Rapid selection of an
573 RNA mimic of green fluorescent protein by fluorescence-based selection and directed
574 evolution. *J Am Chem Soc* **136**, 16299–16308 (2014).
- 575 24. Song, W. *et al.* Imaging RNA polymerase III transcription using a photostable RNA-
576 fluorophore complex. *Nat Chem Biol* **13**, 1187–1194 (2017).
- 577 25. Li, X. *et al.* Imaging Intracellular S-Adenosyl Methionine Dynamics in Live Mammalian
578 Cells with a Genetically Encoded Red Fluorescent RNA-Based Sensor. *J Am Chem Soc*
579 **142**, 14117–14124 (2020).

- 580 26. Chen, X. *et al.* Visualizing RNA dynamics in live cells with bright and stable fluorescent
581 RNAs. *Nat Biotechnol* **37**, 1287–1293 (2019).
- 582 27. Trachman, R. J. *et al.* Structure and functional reselection of the Mango-III fluorogenic
583 RNA aptamer. *Nat Chem Biol* **15**, 472–479 (2019).
- 584 28. Autour, A. *et al.* Fluorogenic RNA Mango aptamers for imaging small non-coding RNAs
585 in mammalian cells. *Nat Commun* **9**, (2018).
- 586 29. Trachman, R. J. *et al.* Structure-Guided Engineering of the Homodimeric Mango-IV
587 Fluorescence Turn-on Aptamer Yields an RNA FRET Pair. *Structure* **28**, 776–785.e3
588 (2020).
- 589 30. Babendure, J., Adams, S. & Tsien, R. Aptamers Switch on Fluorescence of
590 Triphenylmethane Dyes. *Journal of the American Chemical Society* **125**, 14716–14717
591 (2003):
- 592 31. Alam, K. K., Tawiah, K. D., Lichte, M. F., Porciani, D. & Burke, D. H. A Fluorescent Split
593 Aptamer for Visualizing RNA-RNA Assembly in Vivo. *ACS Synth Biol* **6**, 1710–1721
594 (2017).
- 595 32. Karunanayake Mudiyansele, A. P. K. K. *et al.* Genetically Encoded Catalytic Hairpin
596 Assembly for Sensitive RNA Imaging in Live Cells. *J Am Chem Soc* **140**, 8739–8745
597 (2018).
- 598 33. Zhong, W. & Sczepanski, J. T. A Mirror Image Fluorogenic Aptamer Sensor for Live-Cell
599 Imaging of MicroRNAs. *ACS Sens* **4**, 566–570 (2019).
- 600 34. Armitage, B. A. Imaging of RNA in live cells. *Current Opinion in Chemical Biology* **15**,
601 806–812 (2011).
- 602 35. Urbanek, M. O., Galka-Marciniak, P., Olejniczak, M. & Krzyzosiak, W. J. 1083-1095 RNA
603 imaging in living cells - Methods and applications. *RNA Biology* **11**, 1083–1095 (2014).
- 604 36. Aufdembrink, L. M., Khan, P., Gaut, N. J., Adamala, K. P. & Engelhart, A. E. Highly
605 specific, multiplexed isothermal pathogen detection with fluorescent aptamer readout.
606 *RNA* **26**, 1283–1290 (2020).
- 607 37. Kolpashchikov, D. M. Binary malachite green aptamer for fluorescent detection of
608 nucleic acids. *J Am Chem Soc* **127**, 12442–12443 (2005).
- 609 38. Torelli, E. *et al.* Light-Up Split Broccoli Aptamer as a Versatile Tool for RNA Assembly
610 Monitoring in Cell-Free TX-TL Systems, Hybrid RNA/DNA Origami Tagging and DNA
611 Biosensing. *Int J Mol Sci* **24**, 8483 (2023).
- 612 39. Bhadra, S. & Ellington, A. D. A Spinach molecular beacon triggered by strand
613 displacement. *RNA* **20**, 1183–1194 (2014).
- 614 40. Wang, T. & Simmel, F. C. Switchable Fluorescent Light-Up Aptamers Based on
615 Riboswitch Architectures. *Angew. Chem. Int. Ed. Engl.* **62**, e202302858 (2023).
- 616 41. Yan, Z. *et al.* Rapid, multiplexed, and enzyme-free nucleic acid detection using
617 programmable aptamer-based RNA switches. *Chem* **10**, 1–25 (2024).
- 618 42. Zhang, D. Y., Chen, S. X. & Yin, P. Optimizing the specificity of nucleic acid
619 hybridization. *Nat Chem* **4**, 208–214 (2012).
- 620 43. Zadeh, J. N. *et al.* NUPACK: Analysis and design of nucleic acid systems. *J Comput*
621 *Chem* **32**, 170–173 (2011).
- 622 44. Leone, G., Van Schijndel, H., Van Gemen, B., Kramer, F. R. & Schoen, C. D. *Molecular*
623 *Beacon Probes Combined with Amplification by NASBA Enable Homogeneous, Real-*
624 *Time Detection of RNA. Nucleic Acids Research* **26**, 2150–2155 (1998).
- 625 45. Vogels, C. B. F. *et al.* Analytical sensitivity and efficiency comparisons of SARS-CoV-2
626 RT-qPCR primer–probe sets. *Nat Microbiol* **5**, 1299–1305 (2020).

- 627 46. Deiman, B., van Aarle, P., & Sillekens, P. Characteristics and applications of nucleic acid
628 sequence-based amplification (NASBA). *Molecular biotechnology* **20**, 163-179 (2002).
- 629 47. Wang, Q. *et al.* Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB
630 subvariants. *Cell* **186**, 279-286.e8 (2023).
- 631 48. Chakraborty, C. *et al.* The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1,
632 and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and
633 immune escape properties – an alarming global threat of a surge in COVID-19 cases
634 again? *International Journal of Surgery* **109**, 1041–1043 (2023).
- 635 49. Kevadiya, B. D. *et al.* Diagnostics for SARS-CoV-2 infections. *Nature Materials* **20**, 593–
636 605 (2021).
- 637 50. Mathuria, J. P., Yadav, R. & Rajkumar. Laboratory diagnosis of SARS-CoV-2 - A review
638 of current methods. *Journal of Infection and Public Health* **13**, 901–905 (2020).
- 639 51. Martin, D. P. *et al.* The emergence and ongoing convergent evolution of the SARS-CoV-
640 2 N501Y lineages. *Cell* **184**, 5189-5200.e7 (2021).
- 641 52. Paul, S., Nadendla, S. & Sobhia, M. E. Identification of Potential ACE2-Derived Peptide
642 Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational
643 Approaches. *Journal of Physical Chemistry Letters* **13**, 7420–7428 (2022).
- 644 53. Wu, L. *et al.* SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently
645 dominant Delta variant to human ACE2. *Signal Transduction and Targeted Therapy* **7**, 8
646 (2022).
- 647 54. Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D. & Craig, D. W.
648 Translating RNA sequencing into clinical diagnostics: Opportunities and challenges.
649 *Nature Reviews Genetics* **17**, 257–271 (2016).
- 650 55. Chrystoja, C. C. & Diamandis, E. P. Whole genome sequencing as a diagnostic test:
651 Challenges and opportunities. *Clinical Chemistry* **60** 724–733 (2014).
- 652 56. Hashim, H. O. & Al-Shuhaib, M. B. S. Exploring the potential and limitations of PCR-
653 RFLP and PCR-SSCP for SNP detection: A review. *Journal of Applied Biotechnology*
654 *Reports* **6**, 137–144 (2019).
- 655 57. Hanna, R. E. & Doench, J. G. Design and analysis of CRISPR–Cas experiments. *Nature*
656 *Biotechnology* **38**, 813–823 (2020).
- 657 58. Arizti-Sanz, J. *et al.* Simplified Cas13-based assays for the fast identification of SARS-
658 CoV-2 and its variants. *Nat Biomed Eng* **6**, 932–943 (2022).
- 659 59. Pardee, K. *et al.* Paper-based synthetic gene networks. *Cell* **159**, 940–954 (2014).
- 660 60. Green, A. A., Silver, P. A., Collins, J. J. & Yin, P. Toehold switches: De-novo-designed
661 regulators of gene expression. *Cell* **159**, 925–939 (2014).
- 662 61. Kim, J. *et al.* De novo-designed translation-repressing riboregulators for multi-input
663 cellular logic. *Nat Chem Biol* **15**, 1173–1182 (2019).
- 664 62. Ma, D. *et al.* Multi-arm RNA junctions encoding molecular logic unconstrained by input
665 sequence for versatile cell-free diagnostics. *Nat Biomed Eng* **6**, 298–309 (2022).
- 666 63. Chappell, J., Takahashi, M. K. & Lucks, J. B. Creating small transcription activating
667 RNAs. *Nat Chem Biol* **11**, 214–220 (2015).
- 668 64. Oesinghaus, L., & Simmel, F. C. Controlling gene expression in mammalian cells using
669 multiplexed conditional guide RNAs for Cas12a. *Angewandte Chemie International*
670 *Edition*, **60**, 23894-23902 (2021)..
- 671 65. Kocak, D. D. *et al.* Increasing the specificity of CRISPR systems with engineered RNA
672 secondary structures. *Nat Biotechnol* **37**, 657–666 (2019).
- 673 66. Huang, K. *et al.* Structure-based investigation of fluorogenic Pepper aptamer. *Nat Chem*
674 *Biol* **17**, 1289–1295 (2021).

- 675 67. Murray, J. B., Terwey, D. P., Maloney, L., Karpeisky, A., Usman, N., Beigelman, L., &
676 Scott, W. G. *The structural basis of hammerhead ribozyme self-cleavage. Cell* **92**, 665-
677 673 (1998).
- 678 68. Liu, Y., Wilson, T. J., McPhee, S. A. & Lilley, D. M. J. Crystal structure and mechanistic
679 investigation of the twister ribozyme. *Nat Chem Biol* **10**, 739–744 (2014).
- 680 69. Doherty, E. A., & Doudna, J. A. Ribozyme structures and mechanisms. *Annual review of*
681 *biochemistry* **69**, 597-615 (2000).
- 682 70. Giegé, R. Toward a more complete view of tRNA biology. *Nature Structural and*
683 *Molecular Biology* **15**, 1007–1014 (2008).
- 684 71. Suzuki, T. The expanding world of tRNA modifications and their disease relevance.
685 *Nature Reviews Molecular Cell Biology* **22**, 375–392 (2021).
- 686 72. Zapletal, D. *et al.* Structural and functional basis of mammalian microRNA biogenesis by
687 Dicer. *Mol Cell* **82**, 4064-4079.e13 (2022).
- 688 73. Shang, R., Lee, S., Senavirathne, G. & Lai, E. C. microRNAs in action: biogenesis,
689 function and regulation. *Nature Reviews Genetics* **24**, 816–833 (2023).
- 690 74. Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Dynamic RNA Modifications in Gene
691 Expression Regulation. *Cell* **169**, 1187–1200 (2017).
- 692 75. You, M., Litke, J. L., Wu, R. & Jaffrey, S. R. Detection of Low-Abundance Metabolites in
693 Live Cells Using an RNA Integrator. *Cell Chem Biol* **26**, 471-481.e3 (2019).
- 694 76. Menichelli, E. *et al.* Discovery of small molecules that target a tertiary-structured RNA.
695 *Proc Natl Acad Sci U S A* **119**, (2022).
- 696 77. Shraim, A. S., Abdel Majeed, B. A., Al-Binni, M. A. & Hunaiti, A. Therapeutic Potential of
697 Aptamer-Protein Interactions. *ACS Pharmacology and Translational Science* **5**, 1211–
698 1227 (2022).
- 699 78. Geyer, C. R., Colman-Lerner, A., & Brent, R. “Mutagenesis” by peptide aptamers
700 identifies genetic network members and pathway connections. *Proceedings of the*
701 *national academy of sciences* **96**, 8567-8572 (1999).
- 702 79. Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. *Nature Reviews Drug*
703 *Discovery* **9**, 537–550 (2010).
- 704 80. Wang, Q. *et al.* Inert Pepper aptamer-mediated endogenous mRNA recognition and
705 imaging in living cells. *Nucleic Acids Res* **50**, (2022).
- 706 81. Ryckelynck, M. Development and Applications of Fluorogen/Light-Up RNA Aptamer
707 Pairs for RNA Detection and More. *Methods Protoc.* **2166**, 73–102 (2020)
- 708 82. Czarny, P. *et al.* Impact of Single Nucleotide Polymorphisms of Base Excision Repair
709 Genes on DNA Damage and Efficiency of DNA Repair in Recurrent Depression Disorder.
710 *Mol Neurobiol* **54**, 4150–4159 (2017).
- 711 83. Volkova, N. V. *et al.* Mutational signatures are jointly shaped by DNA damage and
712 repair. *Nat Commun* **11**, (2020).
- 713
- 714 84. Smith, M. F. *et al.* Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals,
715 and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant
716 of Concern in Arizona, USA. *mBio* **14**, (2023).
- 717 85. Schäffer, A. A. *et al.* VADR: Validation and annotation of virus sequence submissions to
718 GenBank. *BMC Bioinformatics* **21**, (2020).
- 719 86. Rambaut, A. *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
720 genomic epidemiology. *Nat Microbiol* **5**, 1403–1407 (2020).
- 721



723

724

Fig. 1 | FARSIGHT operating mechanism and initial system characterization.

725 **a**, Design schematic of a conventional toehold exchange probe that consists of two nucleic acid
 726 strands, the probe strand and the protector strand, that are hybridized to each other. The binding
 727 between the probe strand and the target strand results in the protector strand being released
 728 only if the target has the correct sequence.


729 **b**, FARSIGHTs consist of (i) a target-recruiting docking site (shown in green) that is
 730 complementary to a target nucleic acid for promoting contact between RNA target and a hairpin
 731 structure sequestering the stabilizing stem (c^*-b^*) of the aptamer sequence; (ii) toehold exchange
 732 region 1 (TER1) having forward toehold 1 (**a**, shown in amber) and reverse toehold 1 (**d**, shown

733 in lime); (iii) the core reporter aptamer sequence; and (iv) toehold exchange region 2 (TER2)
734 having forward toehold 2 (**b**, shown in black) and reverse toehold 2 (**e**, shown in pink). The RNA
735 target carrying the mutation of interest yields a favorable free energy in the reaction with the
736 FARSIGHT, initiating a branch migration from forward toehold 1 that opens the hairpin stem. The
737 newly released **c*-b*** domain binds to the downstream **b-c** domain in TER2, enabling the
738 fluorescent output from the aptamer/fluorogen complex (ON state). An incorrect target RNA
739 without the expected mutation results in an energy penalty from the mismatched sequence and
740 firmly shifts the equilibrium to OFF state.

741 **c**, Biochemical modeling predicts the FARSIGHT design can detect point mutations in different ranges of
742 $\Delta G_{\text{OFF-INT}}$ and $\Delta G_{\text{INT-ON}}$.

743 **d**, Time-course measurements of fluorescence from a FARSIGHT with a Broccoli reporter
744 aptamer with correct or incorrect synthetic targets that have a single-nucleotide difference, or
745 without a synthetic target.

746 **e**, Photographs of fluorescence from FARSIGHT reactions for discriminating single-nucleotide
747 mutations. Photographs were taken at 0, 5, 10, 15, 20, and 30 min of the reaction using a blue-
748 light transilluminator.




749

750 **Fig. 2 | FARSIGHT discrimination capability of mutations by equilibrium energy**

751 **a**, The differentiation factor of FARSIGHTs with varying binding strength of the four different
 752 toehold domains upon binding to the mutant targets. Reactions were measured in triplicate.

753 **b**, Differentiation factor obtained after a 2 h reaction for each mutated target RNA with single-
 754 nucleotide substitutions including G-U wobble base pairs enables all of them to be distinguished
 755 from the correct target sequence. Inset: Differentiation factor measured for Broccoli FARSIGHTs

756 on a logarithmic scale. Relative errors for the differentiation factor were obtained by adding the
757 relative errors of the FARSIGHT fluorescence measurements with the correct target and the SNP-
758 containing target in quadrature. Relative errors for the correct and SNP-containing target
759 sequence are from the s.d. of $n=3$ technical replicates.



760


761 **Fig. 3 | *In silico* design and discrimination of SARS-CoV-2 mutations by FARSIGHTs with**
 762 **Broccoli output.**

763 **a**, The in silico FARSIGHT design process takes the mutant target sequence to be detected, the
 764 wild-type sequence to be avoided, and the desired aptamer/fluorogen output to generate
 765 candidate FARSIGHTs that are then tested in vitro.

766 **b**, Differentiation factors obtained after 2 h reactions for optimal Broccoli FARSIGHTs determined
 767 in the presence of the correct variant sequence or the wild-type sequence. Individual points
 768 show the fold fluorescence increase from $n=3$ technical replicates. Relative errors for the
 769 differentiation factors were obtained by adding the relative errors of the ON and OFF state
 770 fluorescence measurements in quadrature.

771 **c**, Photographs of FARSIGHTs in **b** after 2 h reactions using a blue-light transilluminator.

772 **d-g**, Time-course measurements of the fluorescence signal from top-performing Broccoli
 773 FARSIGHTs in the presence of the correct mutant variant or wild-type targets. Shaded regions
 774 denote mean \pm s.d. with $n=3$ technical replicates.



775

776 **Fig. 4 | Multiplexed detection of single point mutations by orthogonal FARSIGHTs.**

777 **a**, Schematic of the FARSIGHT design with different output aptamer/fluorogen combinations for
 778 multiplexed mutation detection. Each aptamer has its own sensor RNA that can be
 779 independently activated by its correct mutation-carrying RNA target and induce folding of a
 780 distinct aptamer reporter.

781 **b**, Representative differentiation factor and visual detection of fluorescence from FARSIGHTs
 782 with Red Broccoli/OBI output. Differentiation factors represent mean fluorescence fold increase
 783 of the correct mutant target over the wild-type sequence without the target SNP after 2 h


784 reactions. Relative errors for fold increases were obtained by adding the relative fluorescence
785 errors in quadrature for $n=3$ technical replicates. Photographs were taken using a blue-light
786 transilluminator.

787 **c**, Time-course measurements of fluorescence from the Y505H-targeted Red Broccoli
788 FARSIGHT with correct mutant target or wild-type sequence and without target RNA. Shaded
789 regions denote mean \pm s.d. of $n=3$ technical replicates.

790 **d**, Representative differentiation factor and visual detection of fluorescence from FARSIGHTs
791 with Corn/DFHO output. Differentiation factors represent logarithmic mean fluorescence fold
792 increase of the correct mutant target over the wild-type sequence without the target SNP after
793 2 hr reactions. Relative errors for fold increases were obtained by adding the relative
794 fluorescence errors in quadrature for $n=3$ technical replicates. Photographs were taken using a
795 blue-light transilluminator.

796 **e**, Time-course measurements of fluorescence from the P681H-targeted Corn FARSIGHT with
797 the correct mutant target or wild-type sequence and without target RNA. Shaded regions denote
798 mean \pm s.d. with $n=3$ technical replicates.

799 **f**, Simultaneous multiplexed detection of V1176F, P681H, and Q493R using FARSIGHTs with
800 Broccoli/DFHBI-1T, Corn/DFHO, and Red Broccoli/OBI reporters, respectively. Samples with or
801 without those mutations are applied for a 2 hr FARSIGHT reaction to test the multiplexed
802 mutation analysis performance. Bars denote the mean \pm s.d. of $n=3$ technical replicates.




803

804 **Fig. 5 | Coupling Isothermal amplification with FARSIGHTs to identify SARS-CoV-2 variants**

805 **a**, Schematic of assay workflow for the identification of SARS-CoV-2 variants. An RNA sample
 806 is first amplified using NASBA (nucleic acid sequence-based amplification). The resulting
 807 amplified RNA with the correct target mutant activates the FARSIGHT to produce an output
 808 fluorescence signal to uncover the viral variant.

809 **b-c**, Determination of the detection limit of FARSIGHTs for the F490S S gene mutation of the
 810 XBB Omicron subvariant in SARS-CoV-2 RNA through Red Broccoli/OBI (**b**) and
 811 Broccoli/DFHBI-1T reporters (**c**), respectively. The signal of samples at different concentrations
 812 was obtained as the mean fluorescence intensity \pm s.d. of FARSIGHTs at 2 h, which was
 813 preceded by an 80-minute NASBA reaction. (n = 3 technical replicates; bars represent arithmetic
 814 mean \pm s.d; two-tailed Student's t test; ns, p > 0.05; **, p < 0.01)

815



816

817 **Fig. 6 | Identification of SARS-CoV-2 variants from clinical saliva samples using FARSIGHTs.**

818 **a**, Schematic for simultaneous detection of two mutation hotspots in the SARS-CoV-2 RNA
819 genome to identify virus strains from patient saliva samples. A rapid increase in the fluorescence
820 of Red Broccoli and/or Broccoli FARSIGHTs signifies the presence of the Omicron variant and
821 general SARS-CoV-2 variants (Alpha, Beta, Gamma, and Omicron), respectively.

822 **b**, Red Broccoli FARSIGHTs distinguish Omicron variants from others by detecting the Y505H S
823 gene mutation. General SARS-CoV-2 variants are identified by N501Y-targeted Broccoli
824 FARSIGHTs. ($n=3$ technical replicates; bars represent the arithmetic mean \pm s.d.)
825 **c-d**, Fluorescence signal obtained from 12 clinical positive saliva samples with Omicron BA.5
826 and 11 negative clinical saliva samples after 2 h FARSIGHT reactions ($n=3$ technical replicates,
827 bars represent the arithmetic mean \pm s.d.). Coral circles correspond to Red Broccoli FARSIGHT
828 fluorescence for the Y505H S gene mutation and teal diamonds correspond to Broccoli
829 FARSIGHT fluorescence for the N501Y S gene mutation. The dashed lines represent theoretical
830 diagnostic thresholds that were determined using 95th percentile fluorescence values for non-
831 template controls of Omicron and general SARS-CoV-2 strains (coral dash line: Red Broccoli
832 FARSIGHT threshold value for determining Omicron strains by identifying the Y505H S gene
833 mutation; teal dashed line: Broccoli FARSIGHT threshold value for determining general SARS-
834 CoV-2 variants by identifying the N501Y S gene mutation).